Le Lézard
Classified in: Health, Business
Subject: LIC

PDA Announces Collaboration with the U.S. FDA Concerning Services for Pharma Compounders


The collaboration will extend for four years and include expanded training opportunities and an interactive, in-person and virtual interest group for individuals in the outsourcing facility and compounding pharmacy.

BETHESDA, Md., Feb. 5, 2024 /PRNewswire-PRWeb/ -- PDA is proud to announce a new four-year collaboration with the U.S. Food and Drug Administration's (FDA) Compounding Quality Center of Excellence, established to support outsourcing facilities and related stakeholders in their efforts to provide high-quality drugs for patients who need them. Through the partnership, PDA will expand its current training course opportunities for professionals in the outsourcing facility and compounding community and establish an ongoing interactive in-person and virtual interest group forum.

Pharmaceutical compounding is the process of combining, mixing, or altering ingredients to create a medication tailored to the needs of an individual patient and can be utilized when a patient cannot be treated with an FDA approved drug or in cases of drug shortages or unavailability. Compounding can be performed in pharmacies, hospitals, clinics, and healthcare facilities, or at outsourcing facilities which provide compounded drugs to healthcare facilities without receiving a patient-specific prescription.

"PDA is proud to work with the FDA Compounding Quality Center of Excellence to continue to offer the training curriculum, develop new and exciting training courses and provide an interest group for the professionals in this critical segment of the pharmaceutical industry," said David Talmage, PDA VP of Education.

Michael Porter has joined the PDA Education team to oversee the deployment of the new training courses and to liaise with the FDA. He brings a wealth of experience and expertise to PDA, having worked previously for Pharmatech Associates, a USP Company, PPD, and Eli Lilly.

The training courses will take advantage of the entire gambit of multimedia modalities, including in-person, virtual, and self-guided online training courses. The learning journey is further supported with PDA's new interactive interest group forum established for open conversations about pharmaceutical compounding among leaders in outsourcing facilities, compounding, the FDA, and other committed stakeholders.

In 2024, as part of the Center of Excellence, PDA will offer:

PDA's Compounding Interest Group (IG) will create community collaborations between liked-minded professionals. This new interest group will launch at PDA Week 2024 followed by virtual meetings starting in April and May. A second in-person meeting is scheduled at the 2024 PDA/FDA Joint Regulatory Conference in September.

*Funding for this statement, publication, press release, etc. was made possible, in part, by the Food and Drug Administration through grant (1UE5FD008142). Views expressed in written materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.*

About PDA Education: Built on a reputation of excellence and founded in science, PDA's training courses provide new and experienced professionals alike with practical information and implementable solutions related to essential industry topics.

Media Contact

Walter Morris, www.pda.org, 1 3016565900, [email protected]www.pda.org 

SOURCE www.pda.org


These press releases may also interest you

30 jun 2024
SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug...

30 jun 2024
"AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry." At the 15th Annual Meeting of the New...

30 jun 2024
"AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry." At the 15th Annual Meeting of the New...

30 jun 2024
On June 27, 2024, Yidu Tech Inc. (the ''Company'' or ''Yidu Tech'') (2158.HK), a leader in China's AI medical industry, announced its results for the 2024 fiscal year. During the reporting period, the Company recorded revenue of RMB 807.1 million....

30 jun 2024
Yidu Tech Inc. ("Yidu Tech" or the "Company", together with its subsidiaries and consolidated affiliated entities, the "Group", HKEX: 2158) announced its annual results for the fiscal year ended 31 March 2024 ("FY2024" or the "Reporting Period"). The...

30 jun 2024
CBC Group ("CBC"), Asia's largest healthcare-dedicated asset management firm headquartered in Singapore, announced that its controlled portfolio company, Hasten Biopharmaceutical ("Hasten"), an innovation-driven biopharmaceutical company, has...



News published on and distributed by: